
Truist raised the firm’s price target on Progyny (PGNY) to $42 from $36 and keeps a Buy rating on the shares. The firm increased its FY27/FY28 revenue and adjusted EBITDA
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PGNY | Progyny | 37.15 | 11.94 | 47.37% |
| Name | Price | % Change | |
|---|---|---|---|
| $37.15 | +47.37% |

Truist raised the firm’s price target on Progyny (PGNY) to $42 from $36 and keeps a Buy rating on the shares. The firm increased its FY27/FY28 revenue and adjusted EBITDA

Progyny, Inc. (($PGNY)) has held its Q3 earnings call. Read on for the main highlights of the call. Progyny’s earnings call carried a strongly positive tone, highlighted by record client

Barclays analyst Peter Warendorf raised the firm’s price target on Progyny (PGNY) to $37 from $30 and keeps an Equal Weight rating on the shares. Published first on TheFly –

JPMorgan raised the firm’s price target on Progyny (PGNY) to $35 from $30 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

BofA analyst Allen Lutz raised the firm’s price target on Progyny (PGNY) to $36 from $31 and keeps a Buy rating on the shares after what the firm calls a

Cantor Fitzgerald raised the firm’s price target on Progyny (PGNY) to $35 from $31 and keeps an Overweight rating on the shares. Progyny’s record 2027 selling season and third guidance

Canaccord raised the firm’s price target on Progyny (PGNY) to $36 from $35 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results

Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Progyny (PGNY) to $38 from $37 and keeps an Overweight rating on the shares. A record selling season of

Citizens analyst Constantine Davides raised the firm’s price target on Progyny (PGNY) to $38 from $33 and keeps an Outperform rating on the shares. Published first on TheFly – the

Progyny ( ($PGNY) ) has shared an update. Progyny, Inc. is a global women’s health and family-building company offering fertility and pharmacy benefit services, along with pregnancy, parenting and menopause
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| hold | Reiterated | Nov 11, 2026 | ||||
| hold | Assigned | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Jul 24, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 1, 2027TBA | $2.66B | $0.36 | $356.70M | 2.48 | 31.46 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.